ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Status:
Recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
ANCA-associated vasculitis is an autoimmune disease that causes damage to blood vessels. This
leads to organ damage with the number of organs affected and the severity of damage varying
significantly between patients.
Vasculitis patients also have a very high risk of heart attacks and strokes, called
cardiovascular disease. A chemical called 'endothelin', produced by the blood vessels, causes
vessels to stiffen and raises blood pressure and this associates with cardiovascular risk.
The investigators have previously shown that by blocking the effects of endothelin you reduce
vessel stiffness, lower blood pressure and improve vessel function. However, these studies
only blocked endothelin for a few hours. Now, the investigators would like to see if it is
possible to maintain these benefits by blocking endothelin for longer.
Sparsentan is a tablet that blocks endothelin and lowers blood pressure. The investigators
plan to give sparsentan to patients with vasculitis for 6 weeks. To determine if any
beneficial effects of sparsentan are due to blood pressure lowering the investigators will
give another group of vasculitis patients a tablet called irbesartan which lowers blood
pressure but does not block endothelin. The investigators will compare the results between
the two groups.